ApoE genotyping as a progression-rate biomarker in phase II disease-modification trials for Alzheimer's disease.
Stone
D J
DJ
Molecular Profiling and Research Informatics, Merck Research Laboratories, West Point, PA 19486, USA. david_stone4@merck.com
Molony
C
C
Suver
C
C
Schadt
E E
EE
Potter
W Z
WZ
D000369:Aged, 80 and over; D000483:Alleles; D000544:Alzheimer Disease / Q000188:drug therapy / Q000235:genetics*; D001057:Apolipoproteins E / Q000235:genetics*; D015415:Biomarkers / Q000032:analysis*; D017322:Clinical Trials, Phase II as Topic / Q000379:methods; D003071:Cognition / Q000502:physiology; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male
D001057:Apolipoproteins E; D015415:Biomarkers